Navigation Links
Amira Announces Second DP2 Antagonist Patent Grant in the United Kingdom
Date:5/26/2010

SAN DIEGO, May 26 /PRNewswire/ -- Amira Pharmaceuticals, Inc. today announced that the U.K. Intellectual Property Office has granted patent number GB2461629, titled, "HETEROALKYL ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS," which includes coverage of Amira's AM461 DP2 receptor antagonist.

This is the second patent granted of a large estate filed by Amira Pharmaceuticals that describe novel small molecule inhibitors of the DP2 (CRTH2) receptor.  Amira has successfully completed Phase 1 studies on two DP2 receptor antagonists, AM211 and AM461, and anticipates these compounds will be developed for the treatment of respiratory diseases such as asthma, chronic obstructive pulmonary disease (COPD) and other allergic conditions.

"This UK patent for AM461 is another significant milestone for the Amira DP2 program and clearly shows that Amira can effectively develop patent-protected, novel drug candidates," said John Hutchinson, Ph.D., Vice President of Chemistry.

Bob Baltera, Chief Executive Officer of Amira, added, "This patent demonstrates Amira's continued focus on developing robust programs with strong patent protection, rather than single drug candidates.  We plan to use the same strategy in our continued development of our research programs, including our LPA program."

The newly granted claims cover novel phenoxyphenyl acetic acid compounds, their formulation and uses in Prostaglandin D2 (PGD2)-dependent conditions.  The patent also describes the method of synthesis of this class of DP2 antagonists and their routes of administration for the treatment of DP2 receptor-mediated diseases and conditions.

About Amira

F
'/>"/>

SOURCE Amira Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Amira Pharmaceuticals Submits IND for Second DP2 Antagonist, AM461
2. Amira Pharmaceuticals Announces Initial Positive Phase 1 Clinical Data for AM461, A Back-Up to Amiras Lead DP2 Antagonist, AM211
3. Amira Pharmaceuticals Announces Efficacy of LPA1 Antagonist in a Preclinical Model of Scleroderma
4. Anti-Fibrotic Data from Amira Pharmaceuticals LPA1 Receptor Antagonist Program Published in the British Journal of Pharmacology
5. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
6. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
7. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
8. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
9. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
10. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
11. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/23/2014)... , July 23, 2014 UBM Medica ... – a new online community and information resource for ... manage and treat their patients with neurological disorders ... with an aging population, necessitates greater access to dedicated ...  Key statistics on neurological conditions include: , ...
(Date:7/23/2014)... , July 23, 2014 Research and ... Electrocardiograph (ECG) Market by Product, End-user & by Lead ... their offering. http://photos.prnewswire.com/prnh/20130307/600769 ... segmented into three major segments, namely, holter monitor, resting, ... was valued at $3,683 million in 2013 and is ...
(Date:7/23/2014)... /PRNewswire-iReach/ -- The Centers for Medicare & Medicaid Services ... Improvement Organization (QIN-QIO) contract to a partnership led by ... August 1, WVMI will launch Quality Insights Quality Innovation ... Pennsylvania , Delaware , ... Network will engage providers and the community in multiple, ...
Breaking Medicine Technology:UBM Medica US Launches NeurologyTimes.com 2UBM Medica US Launches NeurologyTimes.com 3Global Diagnostic Electrocardiograph (Resting, Stress, Holter Monitor) (ECG) Market - Forecast to 2020 2Global Diagnostic Electrocardiograph (Resting, Stress, Holter Monitor) (ECG) Market - Forecast to 2020 3Announcing a New Regional Approach to Medicare Quality Improvement 2
(Date:7/23/2014)... Steven Reinberg HealthDay Reporter ... obese and overweight American children and teens look in ... U.S. health officials reported Wednesday. "Being overweight or ... high blood pressure, high cholesterol and diabetes," said lead ... Centers for Disease Control and Prevention,s National Center for ...
(Date:7/23/2014)... Celebrating a decade of philanthropy in 2014, The ... of $1,070,000 in grants to 20 New Jersey non-profit ... Foundation’s 1,000th grant. , “The Horizon Foundation for New ... community-based organizations that are working to improve public health ... State,” said Robert A. Marino, Horizon Blue Cross Blue ...
(Date:7/23/2014)... Painful or itchy skin lesions could be a warning ... have multiple lesions that are suspicious looking, and those ... for non-melanoma skin cancers," study author Dr. Gil Yosipovitch, ... said in a Temple University Health System news release. ... patients who were confirmed to have skin cancer lesions ...
(Date:7/23/2014)... University in Shaanxi province, and the University of California, ... the groundwork for establishing the Sino-U.S. Joint Research Center ... was held in the city of Yingchuan, China, during ... of Agriculture and China,s Ministry of Science and Technology. ... Davis and for our World Food Center and serves ...
(Date:7/23/2014)... DC (PRWEB) July 23, 2014 ... for ATA 2015, ATA’s twentieth annual meeting and ... The meeting, expected to attract over 5,000 attendees ... will take place May 3-5, 2015, in Los ... most renowned healthcare technology professionals from researchers, clinicians, ...
Breaking Medicine News(10 mins):Health News:Many Obese U.S. Kids Think They're Thinner Than They Are 2Health News:Many Obese U.S. Kids Think They're Thinner Than They Are 3Health News:The Horizon Foundation for New Jersey Awards More than $1 million in Grants to 20 Non-profit Organizations 2Health News:The Horizon Foundation for New Jersey Awards More than $1 million in Grants to 20 Non-profit Organizations 3Health News:The Horizon Foundation for New Jersey Awards More than $1 million in Grants to 20 Non-profit Organizations 4Health News:The Horizon Foundation for New Jersey Awards More than $1 million in Grants to 20 Non-profit Organizations 5Health News:Painful, Itchy Patches Could Be Sign of Skin Cancer 2Health News:Global food safety research agreement signed by China and UC Davis 2Health News:Global food safety research agreement signed by China and UC Davis 3Health News:ATA Seeks Speakers to Present at the World’s Largest Telemedicine, mHealth and Telehealth Conference 2
... Case Western Reserve University School of Medicine has developed ... lymphoblastic leukemia (ALL). ALL is the most common type ... each year in the United States. The findings provide ... development of "theranostic" agents-- a treatment platform that combines ...
... HealthDay Reporter , TUESDAY, March 6 (HealthDay News) ... stave off hot flashes, night sweats and other symptoms of ... down the road, a news study says. Hormone replacement ... government-run trial, the U.S. Women,s Health Initiative, was stopped early ...
... assistant professor of computer science and robotics engineering at ... CAREER Award from the National Science Foundation (NSF) to ... purpose robots that can work effectively and productively alongside ... WPI faculty members to receive the CAREER Award, the ...
... Mar 07, 2012-200 million teenagers suffer from depression ... results have led to increased controversy surrounding the ... on the latest research findings on antidepressant medications ... by Journal of Child and Adolescent Psychopharmacology (http://www.liebertpub.com/cap), ...
... at the University of Warwick have used state-of-the-art nuclear ... how pharmaceutical molecules pack together in the solid state. ... NMR magnets, housed at the University of Warwick, to ... and GlaxoSmithKline. The analytical methods look directly ...
... FRANCISCO March 6, 2012 A new paradigm to ... treatment advances that may ultimately vanquish the disease known as ... Ophthalmology , the journal of the American Academy of ... glaucoma solely as an eye disease. Instead, they view it ...
Cached Medicine News:Health News:Researchers develop first 'theranostic' treatment for acute lymphoblastic leukemia (ALL) 2Health News:Estrogen-Only Therapy May Reduce Breast Cancer Risk 2Health News:Estrogen-Only Therapy May Reduce Breast Cancer Risk 3Health News:Estrogen-Only Therapy May Reduce Breast Cancer Risk 4Health News:WPI's Sonia Chernova wins NSF CAREER award for work aimed at creating 'everyday' robots 2Health News:More effective treatments urgently needed for adolescent depression 2Health News:New research characterizes glaucoma as neurologic disorder rather than eye disease 2
... using patented, innovative technology, measures a complete ... only 5 minutes from a simple fingerstick. ... get immediate liver function results. The scope ... only advantage to healthcare providers. The physician, ...
The Strep A Rapid Test Strip is a rapid chromatographic,immunoassay for the qualitative detection of Strep A antigen,from throat swab specimens to aid in the diagnosis of Group A,Streptococcal ...
SAS Strep A Test is a rapid visual test for the presumptive qualitative detection of Group A Streptococcal antigen from throat swab specimens. Group A streptococcus is the principal cause of respirat...
HemataSTAT II has a manual reader. It uses both 0.5 and 1.1 ID capillary tubes., , Spins in just 60 seconds , Built-in reader with LCD display , Accuracy comparable to NCCLS reference method , Lid lo...
Medicine Products: